NCT02937675 2020-11-02A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological MalignanciesEffector TherapeuticsPhase 1/2 Terminated28 enrolled